HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Creates ONE China OTC As Country’s Largest Consumer Health Firm

This article was originally published in The Tan Sheet

Executive Summary

Merging Shanghai Johnson & Johnson and Xian Janssen business divisions makes ONE China OTC the largest consumer health care product company in China. The move “is part of a broader Johnson & Johnson strategic initiative to leverage the company’s breadth and scale in China,” says Mike Hsu, ONE China OTC general manager.

You may also be interested in...

J&J Split To Have Limited China Business Impact?

China is a major emerging market for J&J’s pharma, medical and consumer health businesses and the planned spinout of the consumer business is likely to allow the US giant to focus on key new drugs in a fast-changing and competitive market while retaining medtech growth. But the consumer sector will continue to face challenges and might learn from similar moves by other multinationals in China.

China OTC Drug Sales Pummeled By Pseudoephedrine Restrictions

Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts